Helio Genomics receives 2024 innovation award from California Investment Forum

June 4, 2024
Recognized for application of AI-based medical technology in early cancer detection.

Helio Genomics has been honored by the California Investment Forum (CIF) for its innovations in utilizing AI-based technology in developing its HelioLiver test for early liver cancer detection.

Helio was presented with a 2024 Innovation Award for AI-Based Medical Technology as applied to its HelioLiver. HelioLiver is a multi-analyte blood test that analyzes cell-free DNA (cfDNA), methylation patterns, serum protein markers and demographic information with a simple blood draw to detect hepatocellular carcinoma, or HCC, the most common form of liver cancer.

Criteria for the award included:

·        Innovation

·        Impact

·        Practicality and Scalability

·        Market Performance

·        Academic and Clinical Validation

·        Industry Recognition

Helio Genomics release